valuation thoughts, page-164

I was thinking the same.. I have Celularity in my google email alerts as I have two small parcels at $7 and $5 to get a bit of amniotic/Placental stem cell therapy exposure. Personally I think CHM has alot more to offer hence why my money is here and will continue to direct money here to buy more lower, wasn't the plan but 24.5 cents is an absolute bargain. Speaking of Celularity, Juno therapeutics sold to Celgene for $8b, Celularity is a spinoff from Cellgene. Cellgene was then sold to Bristol Myers Sqibb for $74b. There are some lofty buyouts in this space and CHM are building an impressive pipeline and the first cab of the rank in CHM-1101 is showing some real promise. A Fast track designation could come at anytime. Especially as the results of Cohort 2 would be collated and wrapped up so plenty to show the FDA. Jenn Chow said they are in close discussions with FDA in both the presentations late last year.